About Tokyo Medical University Hospital
東京医科大学病院は、学校法人東京医科大学が運営する大学病院である。 病床数、904床。新宿副都心に位置し、病院本館は1986年の完成当時、日本で最高層の病院建築であった。2019年3月に同敷地内で竣工する新病棟が稼動した後に解体される予定。
- Top Sponsors
- Top Collaborators
- Trials By Phase
- Recruitment Status
- Top Conditions
- Intervention Types
- Top Intervention Names
- Trials By Gender
Clinical Trials at Tokyo Medical University Hospital
During the past decade, Tokyo Medical University Hospital conducted 33 clinical trials. In the 10-year time frame, 33 clinical trials started and 21 clinical trials were completed, i.e. on
average, 63.6% percent of trials that started reached the finish line to date. In the past 5 years, 16 clinical trials started and 15 clinical trials were completed. i.e. 93.8%
of trials that started reached the finish line.
Clinical Trials Sponsors and Collaborators
Out of the total clinical trials conducted in "Tokyo Medical University Hospital" #1 sponsor was "Eli Lilly and Company" with 10 trials, followed by "Amgen" with 4 trials
sponsored, "Pfizer" with 4 trials sponsored, "Bristol-Myers Squibb" with 3 trials sponsored and "Alexion"
with 3 trials sponsored. Other sponsors include 17 different institutions and
companies that sponsored additional 22 trials in total.
In terms of collaborators to trials, out of the total clinical trials conducted in "Tokyo Medical University Hospital"
#1 collaborator was "Japan Lung Cancer Society" with 2 trials as a collaborator, "Merck KGaA, Darmstadt, Germany" with 2 trials as a collaborator, "NSABP Foundation Inc" with 2 trials as a collaborator, "Novartis" with 2 trials as a collaborator and "AstraZeneca" with 1 trials as a collaborator. Other collaborators include 1 different institutions and companies that were
collaborators in the rest 11 trials.
Clinical Trials Conditions at Tokyo Medical University Hospital
According to Clinical.Site data, the most researched conditions in "Tokyo Medical University Hospital" are
"Psoriasis" (6 trials), "Migraine" (4 trials), "Hemophilia A" (3 trials), "Polycythemia Vera (PV)" (2 trials) and "Active Non-segmental Vitiligo" (1 trials). Many other conditions were trialed in "Tokyo Medical University Hospital" in a lesser frequency.
Clinical Trials Intervention Types at Tokyo Medical University Hospital
Most popular intervention types in "Tokyo Medical University Hospital" are "Drug" (34 trials), "Biological" (5 trials), "Device" (5 trials), "Other" (5 trials) and "Procedure" (1 trials). Other intervention types were less common.
The name of intervention was led by "Placebo" (13 trials), "Mirikizumab" (4 trials), "BMS-986165" (3 trials), "Apremilast" (2 trials) and "Avelumab" (2 trials). Other intervention names were less common.
Clinical Trials Genders at Tokyo Medical University Hospital
The vast majority of trials in "Tokyo Medical University Hospital" are
42 trials for "All" genders and 2 trials for "Male" genders.
Clinical Trials Status at Tokyo Medical University Hospital
Currently, there are NaN active trials in "Tokyo Medical University Hospital".
undefined are not yet recruiting,
13 are recruiting,
4 are Active, not recruiting,
and undefined are Enrolling by invitation.
In total, there were 21 completed trials in Tokyo Medical University Hospital,
undefined suspended trials,
and 4 terminated clinical trials to date.
Out of the total trials that were conducted in Tokyo Medical University Hospital, 2 "Phase 1"
clinical trials were conducted, 8 "Phase 2" clinical
trials and 29 "Phase 3" clinical trials were conducted as
well. "Phase 4" trials included 4 trials, and there were
also 2 trials that are defined as “Not Applicable".